Recent studies have demonstrated that genetic deletion or the pharmacological inhibition of PTP1B enhances insulin sensitivity and protects against diet-induced obesity [5,6,7,8], thereby underscoring PTP1B as a crucial therapeutical target for T2DM. This evidence concerns the gene PTPN1 and obesity disorder.